Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Treatment Protocol for Tivozanib vs Sorafenib in Renal Cell Carcinoma (AV-951-09-301)
2009-015987-32Phase 3Completed
- Sponsor
- AVEO Oncology
- Start
- Nov 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tivozanib and sorafenib in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by AVEO Oncology. Primary endpoint: Treatment continuation feasibility. Started Nov 2009; status: completed.
02
Drugs
tivozanibsorafenib
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2009-015987-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015987-32.